Atyr Pharma Inc (NASDAQ:ATYR)’s traded shares stood at 0.75 million during the last session, with the company’s beta value hitting 0.99. At the close of trading, the stock’s price was $3.90, to imply an increase of 0.78% or $0.03 in intraday trading. The ATYR share’s 52-week high remains $4.22, putting it -8.21% down since that peak but still an impressive 63.59% since price per share fell to its 52-week low of $1.42. The company has a valuation of $327.38M, with an average of 0.65 million shares in intraday trading volume over the past 10 days and average of 835.48K shares over the past 3 months.
Atyr Pharma Inc (NASDAQ:ATYR) trade information
After registering a 0.78% upside in the last session, Atyr Pharma Inc (ATYR) has traded red over the past five days. The 5-day price performance for the stock is 1.04%, and 0.26% over 30 days. With these gigs, the year-to-date price performance is 7.73%. Short interest in Atyr Pharma Inc (NASDAQ:ATYR) saw shorts transact 3.52 million shares and set a 3.55 days time to cover.
Atyr Pharma Inc (ATYR) estimates and forecasts
The rating firms project that company’s revenue will shrink -56.70% compared to the previous financial year.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 43.36% for the past 5-year period. While 2025 is set for a 2.84% return in earnings, projections for the next 5 years are at 13.72% annually.
ATYR Dividends
Atyr Pharma Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
We also have Federated Hermes Kaufmann Fund and Federated Hermes Kaufmann Small Cap Fund as the top two Mutual Funds with the largest holdings of the Atyr Pharma Inc (ATYR) shares. Going by data provided on Oct 31, 2024 , Federated Hermes Kaufmann Fund holds roughly 7.85 shares. This is just over 9.35% of the total shares, with a market valuation of $30.61 million. Data from the same date shows that the other fund manager holds a little less at 6.62, or 7.89% of the shares, all valued at about 25.82 million.
